The Iron Paradox: Anemia and Overload in the Same Population

The World Health Organization estimates that roughly 30 percent of women aged 15 to 49 are anemic, and iron deficiency accounts for the majority of those cases. The 2021 WHO global anemia data put the absolute number at over 500 million women worldwide. At the same time, the most common genetic disorder in populations of European ancestry is hereditary hemochromatosis, which causes chronic iron overload and affects roughly 1 in 200 to 1 in 400 individuals depending on the population studied. The paradox is that the same nutrient is simultaneously underconsumed in some populations and accumulating dangerously in others, and clinical advice frequently fails to distinguish between them.

Why Iron Is So Tightly Regulated

The body has no efficient mechanism for excreting iron. Once absorbed, iron is recycled internally as red blood cells are broken down and rebuilt, with only small amounts lost through skin shedding, gut cell turnover, and menstruation in women of reproductive age. Iron balance is therefore maintained almost entirely by regulating absorption rather than excretion.

The hepcidin hormone, produced by the liver, is the master regulator. When iron stores are adequate, hepcidin levels rise and intestinal iron absorption falls. When stores are low or red blood cell production needs to increase, hepcidin falls and absorption rises. The system normally maintains stable body iron content within a narrow range.

This mechanism breaks down in two specific scenarios. The first is when iron losses exceed the maximum absorption capacity, which is what produces iron deficiency anemia. The second is when the regulatory system itself malfunctions, allowing inappropriate absorption regardless of body stores. The genetic mutation responsible for most hereditary hemochromatosis impairs hepcidin signaling, leading to chronic excess absorption over decades.

The Deficiency Side

Camaschella, in a 2019 review in Blood, summarized the modern clinical picture of iron deficiency. Three populations carry most of the disease burden: women of reproductive age (menstrual losses), children under five (rapid growth requiring sustained iron intake), and adults with chronic gastrointestinal blood loss (often undiagnosed). The clinical presentation is highly variable. Severe deficiency produces classic anemia with fatigue, pallor, and shortness of breath. Mild to moderate deficiency may present primarily as cognitive symptoms, exercise intolerance, hair loss, restless legs, or unexplained fatigue without obvious anemia on standard blood counts.

The diagnostic challenge is that a normal hemoglobin level does not rule out iron deficiency. Hemoglobin is a late marker that drops only after iron stores have been substantially depleted. Serum ferritin is a more sensitive early marker, but it is also an acute-phase reactant that rises with inflammation, which can mask deficiency in patients with concurrent inflammatory conditions. The most reliable assessment combines ferritin, transferrin saturation, and clinical context rather than relying on any single marker.

Treatment for confirmed iron deficiency is straightforward in principle. Oral iron supplementation at standard doses corrects most cases over three to six months, with the caveat that gastrointestinal tolerance is poor for many patients. Recent evidence supports alternate-day rather than daily dosing, which improves absorption per dose and reduces side effects. Severe or treatment-refractory cases require intravenous iron, which carries different risks but works reliably when oral routes fail.

The Overload Side

Adams and Barton (2007) reviewed hemochromatosis in the Lancet, and the clinical implications of their summary remain current. The HFE gene mutation responsible for the most common form of hereditary hemochromatosis is present in roughly 1 in 8 individuals of Northern European descent as a heterozygous carrier, and 1 in 200 as a homozygous carrier. Homozygous carriers gradually accumulate iron throughout life, with clinical manifestations typically appearing after age 40 in men and after menopause in women.

The clinical presentation is insidious. Early symptoms include fatigue, joint pain, and unexplained liver enzyme elevations. Later manifestations include diabetes, cardiomyopathy, skin pigmentation changes, and liver cirrhosis. The condition is preventable if identified early and treated with regular phlebotomy, but it is frequently undiagnosed for years because the early symptoms overlap with common complaints in middle-aged adults.

Routine iron supplementation in this population is harmful. A homozygous HFE mutation carrier who takes a standard multivitamin containing 18 mg of iron daily accelerates organ damage. Women in this category benefit from menstrual losses during their reproductive years and become symptomatic after menopause. Men have no equivalent compensating mechanism and become symptomatic earlier.

The Conflict in Population-Level Recommendations

Public health iron recommendations are calibrated to the deficiency-prone majority. Iron-fortified foods, prenatal vitamins with high iron content, and routine iron-containing multivitamins are standard. These recommendations work for the population they were designed for. They are actively harmful for the genetic-overload subpopulation.

The clinical implication is that anyone over age 40 who is taking routine iron supplementation should know whether they have a personal or family history of iron overload before continuing. A simple ferritin and transferrin saturation panel costs little and answers the question definitively. Elevated ferritin with elevated transferrin saturation in an asymptomatic adult is a red flag for hemochromatosis and warrants HFE genetic testing.

The NIH Office of Dietary Supplements iron fact sheet notes both the deficiency and the overload sides of the question, but most consumer-facing material focuses only on deficiency. The result is that iron supplementation continues in populations who do not need it and who may be harmed by it.

The Practical Synthesis

Iron is one of the few nutrients where the right answer depends substantially on individual context. Premenopausal women, pregnant women, growing children, and individuals with documented gastrointestinal blood loss generally benefit from attention to iron intake, including supplementation when indicated by laboratory testing. Adults over 40, particularly men, generally should not take iron supplementation without a documented deficiency, and elevated ferritin in this group warrants further evaluation rather than reassurance.

Dietary iron from food sources rarely causes overload in normal genetic backgrounds, since the regulatory system limits absorption when stores are adequate. The overload risk is primarily from supplementation in people who already have either genetic iron-loading conditions or other forms of dysregulation.

The honest version of iron advice is therefore population-specific rather than universal. The 30 percent of reproductive-age women who are anemic worldwide need more iron. The 0.5 percent of older adults with undiagnosed hemochromatosis need less. The recommendations that work for one group are wrong for the other, and confusing them is one of the more common preventable errors in nutritional self-management.